Drug Information

Rucaparib Granted FDA Approval for Some Recurring Abdominal Cancers

Rucaparib Granted FDA Approval for Some Recurring Abdominal Cancers

By

The US FDA granted approval based on results from ARIEL3, a randomized clinical trial conducted with 561 eligible cancer patients.

FDA Approves Blincyto for B-Cell Precursor ALL in Remission With MRD Presence

FDA Approves Blincyto for B-Cell Precursor ALL in Remission With MRD Presence

By

Accelerated approval was granted by the FDA based on the results of a single-arm trial.

Dabrafenib-Trametinib Combination Approved for Mutation-Positive Thyroid Cancer

Dabrafenib-Trametinib Combination Approved for Mutation-Positive Thyroid Cancer

By

FDA grants approval to immunotherapy combination in the treatment of unresectable and metastatic BRAF V600E mutation-positive anaplastic thyroid cancer (ATC).

Recruitment for 2 Trials of Investigational ADC for Urothelial Cancer Underway

Recruitment for 2 Trials of Investigational ADC for Urothelial Cancer Underway

By

Enfortumab vedotin was granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA), based on interim results from a Phase 1 study.

Moderately Emetogenic Chemotherapy Drug Demonstrates High Emetogenic Potential

Moderately Emetogenic Chemotherapy Drug Demonstrates High Emetogenic Potential

By

Based on results of a prospective and retrospective study evaluating emetogenic potential of 50 chemotherapeutic regimens, researchers suggest changing the classification of irinotecan.

FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment

FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment

By

The US FDA granted approval to fostamatinib (Tavalisse), a kinase inhibitor, for the treatment of thrombocytopenia in patients with chronic IPT who have had an insufficient response to a previous treatment.

National Cancer Drug Shortages Unknown to Many Patients

National Cancer Drug Shortages Unknown to Many Patients

A majority of study respondents reported wanting to be informed about the differences in a drug substitution's efficacy or side effects.

Olanzapine Use to Prevent Chemotherapy-Induced Nausea and Vomiting

Olanzapine Use to Prevent Chemotherapy-Induced Nausea and Vomiting

By

Why is the antipsychotic olanzapine (Zyprexa) being used to prevent nausea?

Blinatumomab Indications Expanded to Include MRD+-B-Cell Precursor ALL

Blinatumomab Indications Expanded to Include MRD+-B-Cell Precursor ALL

By

The US FDA approved expanding the indications for the agent to include pediatric and adult patients with B-cell precursor ALL who have minimal residual disease during or after treatment.

Promising Phase 2 Results Lead to Fast Track Designation for Pancreatic Cancer Drug 

Promising Phase 2 Results Lead to Fast Track Designation for Pancreatic Cancer Drug 

By

FDA Fast Track designation was supported by data from a Phase 2 study reviewing pamrevlumab in combination with gemcitabine and nab-paclitaxel.

Ciprofloxacin Plus Doxycycline Reduces Infection Rate in Multiple Myeloma Post-ASCT

Ciprofloxacin Plus Doxycycline Reduces Infection Rate in Multiple Myeloma Post-ASCT

By

A health outcomes analysis of 419 patients with multiple myeloma sought to determine if cipro-doxy was more effective than cipro alone in reducing the incidence of neutropenic fever and infections, both significant causes of morbidity and death for these patients.

Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer

Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer

By

Results of the phase 3 AXEPT study were used to determine the noninferiority of a modified XELIRI regimen vs a FOLFIRI regimen in terms of overall survival among patients with metastatic colorectal cancer (mCRC).

Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC

Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC

By

According to the FDA, the drug approval is the first to use the end point of metastasis-free survival.

FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages

FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages

By

What is being done to address shortages of chemotherapy drugs?

FDA Upgrades Nivolumab to Regular Approval for Adjuvant Treatment of Advanced Melanoma

FDA Upgrades Nivolumab to Regular Approval for Adjuvant Treatment of Advanced Melanoma

By

The FDA granted approval for nivolumab for adjuvant treatment of some patients with melanoma, based on the results of the CHECKMATE-238 study.

US Pharmacopeia Revises Chapter on Handling Hazardous Drugs

US Pharmacopeia Revises Chapter on Handling Hazardous Drugs

By

What is the USP and what do I need to know about it as an oncology nurse?

Priority Review of New Drug Application Granted to Apalutamide for CRPC

Priority Review of New Drug Application Granted to Apalutamide for CRPC

By

Data from the phase 3 SPARTAN trial prompted the FDA's Priority Review designation for apalutamide.

FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV

FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV

By

FDA issues black box warning for rolapitant regarding the potential for anaphylaxis, anaphylactic shock, and other hypersensitivity reactions in patients receiving the injectable emulsion for CINV prophylaxis.

Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy

Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy

By

A metabolomics study of the effect of palbociclib/letrozole combination on cancer cells discovered that consumption of foods with certain xenoestrogens has a negative effect on the treatment.

Indications for Cabozantinib in Advanced RCC Expanded to First-line Therapy

Indications for Cabozantinib in Advanced RCC Expanded to First-line Therapy

By

The FDA based its approval on data collected from the open-label, phase 2 CABOSUN study, for which researchers randomly assigned 157 patients with RCC to receive oral cabozantinib or sunitinib.

FDA Grants Breakthrough Therapy Designation to Ribociclib for HR+/HER2- Breast Cancer

FDA Grants Breakthrough Therapy Designation to Ribociclib for HR+/HER2- Breast Cancer

By

FDA grants Breakthrough Therapy designation for ribociclib as an initial endocrine-based therapy for HR+/HER2- breast cancer in premenopausal or perimenopausal women.

Venetoclax Effective in Ibrutinib-Failed Chronic Lymphocytic Leukemia

Venetoclax Effective in Ibrutinib-Failed Chronic Lymphocytic Leukemia

By

The efficacy and safety of venetoclax in patients with relapsed/refractory CLL that progressed during or after ibrutinib therapy was determined in an open-label, phase 2 study.

ASHP and Partners Urge Congress to Action on Drug Shortages

ASHP and Partners Urge Congress to Action on Drug Shortages

Groups urge Congress to take immediate action, provide transparency, and improve drug manufacturing.

FDA Approves Biosimilar Trastuzumab-dkst for Breast and Stomach Cancers

FDA Approves Biosimilar Trastuzumab-dkst for Breast and Stomach Cancers

Ogivri was granted FDA approval to treat HER2 breast and gastric or gastroesophageal junction adenocarcinoma cancers.

Opioid Epidemic Response May Be Limiting Cancer-Related Pain Management

Opioid Epidemic Response May Be Limiting Cancer-Related Pain Management

By

A report on current legislation and practice trends regarding opioids and how they are affecting cancer patients' ability to manage their pain.

Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides

Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides

By

The US FDA has granted regular approval to brentuximab vedotin (Adcetris) for pcALCL and CD30-expressing MF in adult patients who received prior systemic therapy.

Alectinib Granted FDA Approval as First-line Therapy for <i>ALK</i>-positive NSCLC

Alectinib Granted FDA Approval as First-line Therapy for ALK-positive NSCLC

By

Approval was based on results from ALEX, for which researchers randomly assigned 303 patients with ALK-positive NSCLC not previously treated with systemic therapy to receive alectinib or crizotinib.

Vemurafenib Granted FDA Approval as First Drug to Treat Erdheim-Chester Disease

Vemurafenib Granted FDA Approval as First Drug to Treat Erdheim-Chester Disease

By

Indications for vemurafenib are expanded to include BRAF V600 mutation-positive Erdheim-Chester disease, an extremely rare non-Langerhans cell histiocytosis. FDA approval is based on results from the phase 2 VE-BASKET study.

FDA Discontinues ESA APPRISE Risk Evaluation and Mitigation Strategy Program

FDA Discontinues ESA APPRISE Risk Evaluation and Mitigation Strategy Program

By

Why was the ESA APPRISE risk evaluation and mitigation strategy program discontinued?

Granulocyte Colony-Stimulating Factors: Use, Administration, Adverse Effects

Granulocyte Colony-Stimulating Factors: Use, Administration, Adverse Effects

By

A review of granulocyte colony-stimulating factors, dosage and administration, adverse effects, and nurse management steps is presented.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs